A Phase II Study of Pembrolizumab With Cisplatin and Gemcitabine Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer

Trial Profile

A Phase II Study of Pembrolizumab With Cisplatin and Gemcitabine Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Cisplatin; Gemcitabine
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms PemCiGem
  • Most Recent Events

    • 31 Jan 2017 Planned End Date changed from 1 Jan 2018 to 1 Jan 2020.
    • 31 Jan 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2020.
    • 05 Feb 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top